These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30617756)

  • 1. Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan.
    Altaani BM; Al-Nimry SS; Haddad RH; Abu-Dahab R
    AAPS PharmSciTech; 2019 Jan; 20(2):54. PubMed ID: 30617756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil.
    Mohammed M; Mansell H; Shoker A; Wasan KM; Wasan EK
    Drug Dev Ind Pharm; 2019 Jan; 45(1):76-87. PubMed ID: 30169982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
    Bagre AP; Jain K; Jain NK
    Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine/hydroxypropyl-β-cyclodextrin/chitosan nanoparticles with sustained release and enhanced anti-inflammation activity.
    Tang P; Sun Q; Zhao L; Pu H; Yang H; Zhang S; Gan R; Gan N; Li H
    Carbohydr Polym; 2018 Oct; 198():418-425. PubMed ID: 30093018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
    Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
    Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
    Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
    Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyelectrolyte Complex Nanoparticles from Chitosan and Acylated Rapeseed Cruciferin Protein for Curcumin Delivery.
    Wang F; Yang Y; Ju X; Udenigwe CC; He R
    J Agric Food Chem; 2018 Mar; 66(11):2685-2693. PubMed ID: 29451796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation.
    Ranjan OP; Shavi GV; Nayak UY; Arumugam K; Averineni RK; Meka SR; Sureshwar P
    Arch Pharm Res; 2011 Nov; 34(11):1919-29. PubMed ID: 22139691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery.
    Jafary Omid N; Bahari Javan N; Dehpour AR; Partoazar A; Rafiee Tehrani M; Dorkoosh F
    Int J Pharm; 2018 Jan; 535(1-2):293-307. PubMed ID: 29138048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of chitosan-based nanoparticles through inter-polymeric complexation for oral drug delivery.
    Jana S; Maji N; Nayak AK; Sen KK; Basu SK
    Carbohydr Polym; 2013 Oct; 98(1):870-6. PubMed ID: 23987423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations.
    Mahjub R; Radmehr M; Dorkoosh FA; Ostad SN; Rafiee-Tehrani M
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1645-59. PubMed ID: 24093431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Delivery of Teriparatide Using a Nanoemulsion System: Design, in Vitro and in Vivo Evaluation.
    Altaani BM; Almaaytah AM; Dadou S; Alkhamis K; Daradka MH; Hananeh W
    Pharm Res; 2020 Apr; 37(4):80. PubMed ID: 32253527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration.
    Hecq J; Siepmann F; Siepmann J; Amighi K; Goole J
    Drug Dev Ind Pharm; 2015; 41(12):2037-44. PubMed ID: 26006329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of combined nanocarrier system based on chitosan nanoparticles and phospholipids complex for improved delivery of ferulic acid.
    Telange DR; Jain SP; Pethe AM; Kharkar PS; Rarokar NR
    Int J Biol Macromol; 2021 Feb; 171():288-307. PubMed ID: 33418046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
    Mahmoud AA; El-Feky GS; Kamel R; Awad GE
    Int J Pharm; 2011 Jul; 413(1-2):229-36. PubMed ID: 21540097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new controlled-release liquid delivery system based on diclofenac potassium and low molecular weight chitosan complex solubilized in polysorbates.
    Athamneh NA; Tashtoush BM; Qandil AM; Al-Tanni BM; Obaidat AA; Al-Jbour ND; Qinna NA; Al-Sou'od K; Al-Remawi MM; Badwan AA
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1217-29. PubMed ID: 22873834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate.
    Yang X; Trinh HM; Agrahari V; Sheng Y; Pal D; Mitra AK
    AAPS PharmSciTech; 2016 Apr; 17(2):294-306. PubMed ID: 26085051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
    He W; Horn SW; Hussain MD
    Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of Chitosan Okra Nanoparticles: Optimization and Evaluation as Mucoadhesive Drug Delivery System.
    Brar V; Kaur G
    Pharm Nanotechnol; 2018; 6(3):180-191. PubMed ID: 30101724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and optimization of PMAA-chitosan-PEG nanoparticles for oral drug delivery.
    Pawar H; Douroumis D; Boateng JS
    Colloids Surf B Biointerfaces; 2012 Feb; 90():102-8. PubMed ID: 22037474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.